Sort by
Refine Your Search
-
salary of $70,000 per year and additional funds for research expenses. The initial appointment will be for two years with extension to the third year depending on satisfactory performance. Basic
-
condensed matter (material growth) and AMO (optical spectroscopy). The appointment could begin as early as February 1, 2026, and is initially for one year, with the possibility of renewal for an additional 1
-
funding from the National Institutes of Health (NIH) in 2021, setting a school record for research funding for the sixth straight year. Additionally, IUSM provides an interdisciplinary and interactive
-
. The appointment will initially be for one year, with the possibility of extension for up to an additional two years. More information about the group and the IU Physics Department can be found at: https
-
universities. Terms of Agreement Fellows are expected to pursue research, oversee student research, and participate in the intellectual life of the lab. Fellowships are expected to be 2-year positions; fellows
-
Anticipated Start Date: Spring or Summer 2026 (flexible) Salary: $60,000 + benefits Work Schedule: Full-time, on-campus Supervisors: Dr. Tim Pleskac and Dr. David Crandall Initial Appointment: 1 year, with
-
: The appointment begins July 1, 2026, and is a 1-year appointment, renewable for up to 2 years. Salary / Benefits: Salary and benefits are competitive. Basic Qualifications Required Qualifications: Applicants must
-
be given to candidates who submit materials before March 1. Appointment term: The appointment begins July 1, 2026, and is a 1-year appointment, renewable for up to 2 years. Salary / Benefits: Salary
-
is renewable with an initial appointment for one year and offers a generous salary and benefits package. Review of applications will begin on February 15, 2025 and will continue until the positions
-
. The initial appointment for this position will be for 2 years. Additional 1 year extension will be available based on performance, mutual agreement, and funding availability of the phase II